There is a small irony embedded in the name “Hypospray.” Star Trek fans — and there are, apparently, many of them working in pharmacology — will recognize the hypospray as the medical device used by Dr. McCoy, Dr. Crusher, and various other starship physicians to administer medications through the skin without needles. Gene Roddenberry’s writers invented it in 1966 because NBC’s broadcast standards prohibited showing hypodermic syringes on television, which is perhaps the most mundane origin story for any piece of iconic science fiction technology.
The real-world Hypospray is different from the fictional one in important ways. It does not inject through the skin under pressure. It does not work through clothing. It is, specifically and precisely, a topical transdermal delivery platform — meaning it is applied to the surface of the skin, where the drug subsequently absorbs through the skin’s own barrier layers by diffusion rather than by force. This distinction matters clinically and it matters for patient expectations. The Hypospray does not penetrate the skin. It delivers to the skin. The skin does the rest.
That said, the functional aspiration has always been the same: get drugs into the body efficiently, comfortably, and without a needle.
What TDSC Built
The Hypospray platform was developed by Transdermal Delivery Solutions Corp (TDSC). The core technology is a proprietary formulation system designed to improve the skin’s permeability to active pharmaceutical ingredients — particularly hormone compounds — and to deliver those compounds through a metered-dose spray format.
The formulation system addresses the fundamental challenge of transdermal delivery: the stratum corneum is very good at keeping things out. It is the biological equivalent of a well-sealed wall. Getting molecules through it requires either a high-concentration gradient (lots of drug on the outside, so some diffuses through), chemical penetration enhancers (agents that temporarily modify the stratum corneum’s structure to increase permeability), or physical disruption (microneedles, ultrasound — neither of which is the Hypospray approach).
The TDSC platform uses the formulation chemistry route: a combination of ethanol, penetration-enhancing agents, and other excipients that create conditions favorable for testosterone (and other compounds) to diffuse through the stratum corneum and into the viable epidermis and dermis. The carrier solution is volatile, evaporating rapidly from the skin surface after application. This behavior directly addresses the transfer problem identified in Post 2 — less surface residue, reduced transfer window.
The TDS-testosterone system (the precursor formulation studied in clinical pharmacokinetic research) was validated as bioequivalent to AndroGel 1% in the 2006 Chik et al. study at the William Harvey Research Institute. The spray delivered the same systemic testosterone exposure over 12 hours as the market-leading gel, with the key practical advantages of rapid drying and reduced residue.
The Product Line: What Hypospray Delivers
The Hypospray platform is not a single-molecule delivery system. It is designed as a platform for multiple hormone and peptide compounds. Keen Meds has built its entire prescription product line on this delivery method.
For men’s testosterone therapy, three strengths are available:
- 10 mg — suitable for starting doses and dose titration
- 15 mg — mid-range dosing
- 20 mg — higher end of physiological replacement range
These correspond to the range that keeps most hypogonadal men in the target total testosterone window of 400–700 ng/dL when applied daily to clean, dry skin on the shoulders or upper arms.
For women’s testosterone therapy — a significantly underserved clinical area — three strengths at dramatically lower doses:
- 0.5 mg
- 1 mg
- 2 mg
Women require approximately 1/20th to 1/10th the testosterone dose that men require for physiological replacement. The precision of a metered spray format is particularly valuable here: the difference between 0.5 mg and 2 mg is clinically significant, and a format that reliably delivers exactly what’s prescribed matters considerably.
Beyond testosterone, the Hypospray platform at Keen Meds extends to:
- Estradiol (0.05 mg, 0.1 mg, 0.15 mg) — for women’s hormone therapy
- Progesterone (1 mg, 2.5 mg, 5 mg) — transdermal progesterone for HRT
- Tirzepatide (2.5 mg through 15 mg, six strengths) — the GLP-1/GIP agonist applied topically
- Liraglutide (0.6 mg through 3 mg, five strengths) — GLP-1 agonist delivered transdermally
- BPC-157 (200 mcg, 300 mcg, 500 mcg) — peptide compound for tissue support
This breadth matters more than it might initially appear. The vision embedded in the Hypospray platform is not merely “a better way to give testosterone.” It is a general-purpose delivery infrastructure for hormone and peptide compounds that are currently administered by injection, with all the friction, pain, disposal logistics, and adherence challenges that entails.
Why This Is Clinically Different From Generic Gel
The question any thoughtful prescriber or patient should ask is: how is this different from a compounded testosterone cream or gel from any compounding pharmacy?
The answer has multiple layers.
First, the formulation chemistry. A compounded testosterone cream is typically a base (commonly HRT-Cream or similar) with testosterone dissolved or suspended in it. The absorption characteristics depend heavily on the base, and compounded preparations vary between pharmacies and even between batches. A platform technology like Hypospray uses a defined, validated carrier system specifically engineered for transdermal flux — the penetration enhancer chemistry is the product, not just incidental to it.
Second, dose consistency. A metered spray pump delivers a calibrated volume per actuation with high reproducibility. A cream scooped from a jar does not. For low-dose products like women’s 0.5 mg testosterone, consistent actuation-to-actuation delivery isn’t optional — it is the foundation of therapeutic reliability.
Third, the transfer profile. The volatile carrier of the spray formulation dries rapidly, as documented in the Chik et al. pharmacokinetic study. A cream or thick gel does not.
The Vision: Replacing the Needle, Not Just for Testosterone
TDSC’s clinical program has not been limited to testosterone. The expansion to GLP-1 agonists like tirzepatide and liraglutide represents the more ambitious version of the platform thesis: that the transdermal spray route can replace subcutaneous injection for a growing class of peptide and hormone therapies that patients currently self-inject.
Weekly subcutaneous injections of GLP-1 agonists are effective, but the compliance picture is complicated by needle anxiety, site reactions, and the logistics of refrigerated injectable products. A topical daily spray, if it can achieve comparable bioavailability — the key clinical question currently being investigated — would represent a genuine quality-of-life improvement for millions of patients on weight management therapy.
Whether the peptide pharmacokinetics work out at clinically relevant doses is still being established. The testosterone data, at least, is in hand: the spray delivers the hormone, at physiological levels, without the needle.
Next up: The final post in Series 9 pulls the entire narrative arc together — from Berthold’s roosters in 1849 to the transdermal spray today — and makes the case that precision topical delivery is the logical endpoint of the entire testosterone science story.
